GEA
ESPR

Glen Eagle Advisors’s Esperion Therapeutics ESPR Stock Holding History

Glen Eagle Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-110
Closed -$1.33K – 984
2021
Q3 		$1.33K Hold
110
– – ﹤0.01% 971
2021
Q2 		$2.33K Hold
110
– – ﹤0.01% 903
2021
Q1 		$3.09K Sell
110
-155
-58% -$4.57K ﹤0.01% 829
2020
Q4 		$6.89K Buy
265
+85
+47% +$2.55K ﹤0.01% 689
2020
Q3 		$6.69K Buy
180
+20
+13% +$792 ﹤0.01% 659
2020
Q2 		$8.21K Hold
160
– – ﹤0.01% 595
2020
Q1 		$5.04K Buy
160
+30
+23% +$1.58K ﹤0.01% 615
2019
Q4 		$7.75K Hold
130
– – ﹤0.01% 641
2019
Q3 		$4.77K Hold
130
– – ﹤0.01% 642
2019
Q2 		$6.05K Buy
130
+50
+63% +$2.35K ﹤0.01% 596
2019
Q1 		$3.21K Buy
+80
New +$3.59K ﹤0.01% 620

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Glen Eagle Advisors's ESPR Position: Q4 2021 in Review

Glen Eagle Advisors sold out of Esperion Therapeutics (ESPR) in Q4 2021, closing a stake of 110 shares — an estimated $1.33K sold.

Glen Eagle Advisors first reported a position in ESPR in Q1 2019 and held it in 11 quarters. The position peaked at $8.21K in Q2 2020. 133 funds tracked by Wall St. Rank hold ESPR as of Q4 2021.

  • Glen Eagle Advisors reported no remaining Esperion Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Glen Eagle Advisors sold 110 Esperion Therapeutics shares in Q4 2021, an estimated $1.33K.
  • Glen Eagle Advisors first reported a position in Esperion Therapeutics in Q1 2019 and held it in 11 quarters.
  • Glen Eagle Advisors's Esperion Therapeutics position peaked at $8.21K in Q2 2020.
  • 133 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2021.

Based on Glen Eagle Advisors's 13F filing for Q4 2021, filed 13 Aug 2024.